tbuckley/cabot-search huggingface dataset:
A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (&gt;60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States
Authors: Vamsi Kota, Prachi Karkhanis, Rashmi Sharma, Sheldon Bolds, Kaitlin Sitchenko, Anima Shrestha, Veeraen Jonnalagadda, Manila Gaddh, Leon Bernal-Mizrachi, Leonard T. Heffner, Elliott F. Winton, Morgan L. McLemore, Amelia Langston, Jacques Galipeau, Imre Bodó, Zaid Al-Kadhimi, Asad Bashey, Robert K. Stuart, Sarah I. Vidito, Asim Pati, Jonathan M. Gerber, Michael R. Grunwald, Kyle T. Bradley, Jose Tongol, Mohamed El-Geneidy, Hanna Jean Khoury, Martha Arellano, Anand Jillella
Journal: Blood (2016)
Association Between Maternal Body Mass Index in Early Pregnancy and Incidence of Cerebral Palsy
Authors: Eduardo Villamor, Kristina Tedroff, Mark Peterson, Stefan Johansson, Martin Neovius, Gunnar Petersson, Sven Cnattingius
Journal: JAMA (2017)

<h3>Importance</h3> Maternal overweight and obesity are associated with increased risks of preterm delivery, asphyxia-related neonatal complications, and congenital malformations, which in turn are associated with increased risks of cerebral palsy. It is uncertain whether risk of cerebral palsy in offspring increases with maternal overweight and obesity severity and what could be possible mechanisms. <h3>Objective</h3> To study the associations between early pregnancy body mass index (BMI) and rates of cerebral palsy by gestational age and to identify potential mediators of these associations. <h3>Design, Setting, and Participants</h3> Population-based retrospective cohort study of women with singleton children born in Sweden from 1997 through 2011. Using national registries, children were followed for a cerebral palsy diagnosis through 2012. <h3>Exposures</h3> Early pregnancy BMI. <h3>Main Outcomes and Measures</h3> Incidence rates of cerebral palsy and hazard ratios (HRs) with 95% CIs, adjusted for maternal age, country of origin, education level, cohabitation with a partner, height, smoking during pregnancy, and year of delivery. <h3>Results</h3> Of 1 423 929 children included (mean gestational age, 39.8 weeks [SD, 1.8]; 51.4% male), 3029 were diagnosed with cerebral palsy over a median 7.8 years of follow-up (risk, 2.13 per 1000 live births; rate, 2.63/10 000 child-years). The percentages of mothers in BMI categories were 2.4% at BMI less than 18.5 (underweight), 61.8% at BMI of 18.5 to 24.9 (normal weight), 24.8% at BMI of 25 to 29.9 (overweight), 7.8% at BMI of 30 to 34.9 (obesity grade 1), 2.4% at BMI of 35 to 39.9 (obesity grade 2), and 0.8% at BMI 40 or greater (obesity grade 3). The number of cerebral palsy cases in each BMI category was 64, 1487, 728, 239, 88, and 38; and the rates per 10 000 child-years were 2.58, 2.35, 2.92, 3.15, 4.00, and 5.19, respectively. Compared with children of normal-weight mothers, adjusted HR of cerebral palsy were 1.22 (95% CI, 1.11-1.33) for overweight, 1.28 (95% CI, 1.11-1.47) for obesity grade 1, 1.54 (95% CI, 1.24, 1.93) for obesity grade 2, and 2.02 (95% CI, 1.46-2.79) for obesity grade 3. Results were statistically significant for children born at full term, who comprised 71% of all children with cerebral palsy, but not for preterm infants. An estimated 45% of the association between maternal BMI and rates of cerebral palsy in full-term children was mediated through asphyxia-related neonatal morbidity. <h3>Conclusions and Relevance</h3> Among Swedish women with singleton children, maternal overweight and obesity were significantly associated with the rate of cerebral palsy. The association was limited to children born at full term and was partly mediated through asphyxia-related neonatal complications.
Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway
Authors: Junping Xin, Dewen You, Andrew Volk, Jun Zhang, Jing Li, Rachel Schmidt, Allen Ni, Grace Ng, Wei Wei, Zhixin Xia, Yechen Xiao, Rafael Gutierrez, Jerry Pan, Peter Breslin, Haiyan Chen, Paul C Kuo, Sucha Nand, Jianke Zhang, Jianjun Chen, Jiwang Zhang
Journal: Blood (2014)
Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
Authors: Elad Sharon
Journal: Clinical Cancer Research (2017)

Champiat and colleagues suggest that a small subset of patients at their center treated with PD1/PDL1 inhibitors appear to exhibit hyperprogression of disease. This commentary goes over some limitations in their preliminary analysis, a possible mechanism to explain the phenomenon, and a means by which other investigators can attempt to validate and further characterize these results. Clin Cancer Res; 23(8); 1879-81. ©2017 AACRSee related article by Champiat et al., p. 1920.
The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study
Authors: Jonathan Moreira, Kari Rabe, James R Cerhan, John Wilson, Neil Kay, Clive S. Zent, Deborah Bowen, Jose F. Leis, Susan L Slager, Susan Schwager, Randy F Wendt, Timothy G Call, Curtis A. Hanson, Tait D. Shanafelt
Journal: Blood (2011)
Abstract BS2-1: A role of extracellular miRNA in breast cancer metastasis
Authors: SE Wang
Journal: Cancer Research (2017)

Abstract Extracellular microRNAs (miRNAs) that can be detected in the circulation are novel mediators of intercellular communication and are considered emerging biomarkers for human diseases. Using cell-secreted extracellular vesicles (e.g., exosomes) as vehicles, miRNAs secreted by cancer cells can travel to and enter various types of niche cells in primary and pre-metastatic tumor microenvironments. Upon entering niche cells, miRNAs regulate gene expression to prepare the niche for cancer progression. Our lab focuses on defining the roles of breast cancer secreted miRNAs in adapting local and distal niche cells and tissues in cancer progression and metastasis. Through de novo sequencing and PCR of circulating small RNAs in the pre-treatment sera of stage II-III breast cancer patients we identified circulating miRNAs as biomarkers for cancer progression to metastatic disease. Subsequent mechanistic studies revealed important functions of breast cancer secreted miRNAs in various aspects of cellular behaviours. Our lab is currently exploring additional mechanisms through which breast cancer-derived, extracellular miRNAs contribute to the multifaceted reprogramming of non-cancerous cells in the tumor microenvironment as well as novel therapeutic strategies targeting cancer-derived extracellular miRNAs for their function in cancer-host communication. Citation Format: Wang SE. A role of extracellular miRNA in breast cancer metastasis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr BS2-1.
a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.
Authors: Ying Ye, Michael McDevitt, Mingzhou Guo, Judith E. Karp, Steve Gore, Hetty Carraway, Xiaofei Wang, Oliver Galm, Jaroslaw Maciejewski, Andrew Dunbar, Lukasz Gondek, Doug B. Smith, Steve Allen, Craig Hooker, James G. Herman
Journal: Blood (2007)
Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.
Authors: Andrew M Evens, Weiyun Ai, Sriram Balasubramanian, Mint Sirisawad, Chitra Mani, Martha Guerra, Nancy Szakacs, David Loury, Joseph J Buggy, Ahmed Hamdy, Julie M. Vose, Nancy L Bartlett
Journal: Blood (2009)
First data from the the Patient's Anastrozole Compliance to Therapy Programme evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer
Authors: C. Jackisch, N. Harbeck, M. Blettner, P. Hadji, H. Lück, D. C. Schmidt, R. Haidinger, B. Gutendorf, R. Kreienberg
Journal: Journal of Clinical Oncology (2009)

e11592 Background: Retrospective pharmacy data suggest that within the first year of therapy patients’ pick-up rate of aromatase inhibitor (AI) packs prescribed for early breast cancer (EBC) drops below 70%. Little is known about compliance to AI and patient motivation outside of clinical trials and the effect of compliance on patient outcome. Methods: The Patient´s Anastrozole Compliance to Therapy (PACT) programme, a two arm, randomized parallel group trial with 60 months follow-up, randomized postmenopausal women with HR+ EBC receiving anastrozole as adjuvant treatment and who consented to participate, to routine clinical care alone or additional standardized information consisting of 9 mailings of brochures and letters over the first 12 months following initiation of therapy. Primary endpoint is compliance rate in the standard versus intervention arm after 12 months, secondary endpoints include safety, reasons for non-compliance, influence of baseline characteristics, and of compliance on clinical outcome parameters. Compliance was evaluated by patient self reporting via standardized questionnaires, cross-checks of prescription data from hospital records and physician recall. QoL and patients’ satisfaction are assessed with standard questionnaires. Results: From Jul 2006 to Nov 2008, 4,924 patients were enrolled. Demographic data and baseline characteristics including median age, disease parameters, BMI, QoL at study start, co-morbidities and concomitant medication will be presented Conclusions: As of today, PACT is the largest prospective investigation on compliance to AI. It will provide valuable insights into the reasons for non-compliance to adjuvant AI therapy and demonstrate if a simple intervention such as standardized written information throughout the first treatment year may improve compliance and patient outcome. [Table: see text]
Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)
Authors: Kiran Naqvi, Guillermo Garcia-Manero, Carlos E. Bueso-Ramos, Sherry Pierce, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Stefan Faderl, Hagop M. Kantarjian, Elias Jabbour
Journal: Blood (2010)
A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb
Authors: J.S. Davis, C. Mackrow, P. Binks, W. Fletcher, P. Dettwiller, C. Marshall, J. Day, W. Pratt, S.Y.C. Tong
Journal: Clinical Microbiology and Infection (2017)
Exercise capacity at 18 years of age in two extremely preterm born cohorts from the 1980's and 1990's
Authors: Hege Clemm, Maria Vollsæter, Einar Thorsen, Ola Røksund, Thomas Halvorsen
Journal: European Respiratory Journal (2014)

Introduction  Physical activity (PA) contributes to a healthy lifestyle; however, in subjects born extremely preterm (EP) both reduced PA and exercise capacity has been reported.   Aim  To examine relationships between PA and exercise capacity in adolescents born EP and at term in two different decades.   Methods  Two area-based cohorts born at gestational age ≤28 weeks or with birth weight ≤1000 grams in 1982-85 and 1991-92 and matched term-born controls were examined with standardized maximal cardiopulmonary treadmill exercise tests at 18 years of age in 2001 and 2008, respectively. Background data were obtained from questionnaires, and statistical analyses were adjusted for gender.   Results  In the 1980-cohort (40/46 born EP vs. 46/46 controls) mean peakVO 2  (ml/kg/min) was 47.1 vs. 49.3 (p=0.226), peakVO 2  (L/min) 3.0 vs. 3.3 (p=0.012) and the treadmill distance (meters) 997 vs. 1079 (p=0.062). In the 1990-cohort (26/31 born EP vs. 22/28 controls) the respective results were 42.3 vs. 45.3 (p=0.040), 2.7 vs. 3.0 (pl0.001) and 915 vs. 1017 (p=0.022). Exercise capacity was similar in term controls born in the two decades, whereas mean peakVO 2  (ml/kg/min) was lower in the group born EP in the 19909s (p=0.032); however, interaction terms were not significant. PA was higher in the 1990-cohort (p=0.002), but similarly and positively associated with exercise capacity in both cohorts.   Conclusion  Compared to controls born at term, exercise capacity was modestly reduced in 18 year old subjects born EP, more so for those born in the 19909s than in the 19809s. PA and peakVO 2  were similarly associated in adolescents born EP and at term in both decades indicating similar benefits from PA.
Pharmacological Inhibition of Calpain-1 Prevents Red Cell Dehydration and Reduces Gardos Channel Activity in a Mouse Model of Sickle Cell Disease. Identification of Druggable Protease Target
Authors: Lucia De Franceschi, Alessandro Mattè, Carlo Brugnara, Angela Siciliano, Mariarita Bertoldi, Adam Wieschhaus, Athar H. Chishti
Journal: Blood (2011)
Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.
Authors: Neal S. Young, Elisabetta Antonioli, Bruno Rotoli, Hubert Schrezenmeier, Jörg Schubert, Alvaro Urbano-Ispizua, Luke Coyle, Carlos de Castro, Chieh-Lin Fu, Jaroslaw P. Maciejewski, Christopher F. Mojcik, Russell P. Rother, Peter Hillmen
Journal: Blood (2006)
Listerine May Help Control Spread of Gonorrhea
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices
Authors: John P. Boehmer, Ramesh Hariharan, Fausto G. Devecchi, Andrew L. Smith, Giulio Molon, Alessandro Capucci, Qi An, Viktoria Averina, Craig M. Stolen, Pramodsingh H. Thakur, Julie A. Thompson, Ramesh Wariar, Yi Zhang, Jagmeet P. Singh
Journal: JACC Heart Failure (2017)

The aim of this study was to develop and validate a device-based diagnostic algorithm to predict heart failure (HF) events.HF involves costly hospitalizations with adverse impact on patient outcomes. The authors hypothesized that an algorithm combining a diverse set of implanted device-based sensors chosen to target HF pathophysiology could detect worsening HF.The MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study enrolled patients with investigational chronic ambulatory data collection via implanted cardiac resynchronization therapy defibrillators. HF events (HFEs), defined as HF admissions or unscheduled visits with intravenous treatment, were independently adjudicated. The development cohort of patients was used to construct a composite index and alert algorithm (HeartLogic) combining heart sounds, respiration, thoracic impedance, heart rate, and activity; the test cohort was sequestered for independent validation. The 2 coprimary endpoints were sensitivity to detect HFE >40% and unexplained alert rate <2 alerts per patient-year.Overall, 900 patients (development cohort, n = 500; test cohort, n = 400) were followed for up to 1 year. Coprimary endpoints were evaluated using 320 patient-years of follow-up data and 50 HFEs in the test cohort (72% men; mean age 66.8 ± 10.3 years; New York Heart Association functional class at enrollment: 69% in class II, 25% in class III; mean left ventricular ejection fraction 30.0 ± 11.4%). Both endpoints were significantly exceeded, with sensitivity of 70% (95% confidence interval [CI]: 55.4% to 82.1%) and an unexplained alert rate of 1.47 per patient-year (95% CI: 1.32 to 1.65). The median lead time before HFE was 34.0 days (interquartile range: 19.0 to 66.3 days).The HeartLogic multisensor index and alert algorithm provides a sensitive and timely predictor of impending HF decompensation. (Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices [MultiSENSE]; NCT01128166).
Assessment of the Parameters of Myeloma Bone Disease Signaling to the Extent of Skeletal Involvement, Bone Mineral Turnover and Activity of Multiple Myeloma
Authors: Jiri Minarik, Zuzana Hermanova, Pavla Petrova, Jana Zapletalova, Jan Hrbek, Petra Pusciznova, Jaroslav Bacovsky, Tomas Pika, Miroslav Herman, Vlastimil Scudla
Journal: Blood (2015)
Hospitalization Rates Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report From the Childhood Cancer Survivor Study (CCSS).
Authors: Vikki G Nolan, Beth Kurt, Kirsten K Ness, Joseph P. Neglia, Jean Tersak, Melissa M. Hudson, Gregory Armstrong, Wendy Leisenring, Leslie L. Robison, Mukta Arora
Journal: Blood (2009)
R-spondin1 Promotes Paneth Cell Growth, Maintains Intestinal Microbial Ecology, and Ameliorates GvHD
Authors: Eiko Hayase, Daigo Hashimoto, Kiminori Nakamura, Yoshitoshi Ogura, Tetsuya Hayashi, Ken Kurokawa, Tokiyoshi Ayabe, Takanori Teshima
Journal: Blood (2015)
Incidence and Differential Diagnosis of Human Herpes Virus-6 Associated Encephalitis/Myelitis in Allogeneic Stem Cell Transplantation That Mimics Calcineurin Inhibitor-Induced Pain Syndrome
Authors: Goichi Yoshimoto, Toshihiro Miyamoto, Koji Kato, Yasuo Mori, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Koichi Akashi
Journal: Blood (2015)
Abstract P2-04-24: Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer
Authors: YJ Choi, JH Lee, SY Moon, JY Choi, SP Jung, JW Bae, KH Park
Journal: Cancer Research (2017)

Abstract Background Recently, the balance in immune system between immune surveillance and tolerance is known to be associated with the prognosis of breast cancer patients. The aim of this study was to investigate changes of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand1 (PD-L1) status after neoadjuvant chemotherapy (NAC) and their impact on recurrence in patients with locally advanced breast cancer. Methods Paired samples (before and after NAC) of triple negative or HER2+ breast cancer tissue were obtained from clinical stage II or III patients (n=39) undergoing NAC and subsequent breast resection. The assessment of immunohistochemical (IHC) staining for PD-L1 were performed. Immunostaining of forkhead box P3 (Foxp3) and CD4/CD8 were performed for subtyping of TILs in triple negative breast cancer (TNBC) only. Clinicopathologic data including baseline characteristics, tumor response and recurrence were reviewed. Results Proportion of PD-L1 (+) tumor cells in pre-chemotherapy tissue was 20% (5/25) in HER2+ and 28.6% (4/14) in TNBC. It could not predict pathologic complete response. Most post-chemotherapy tissue (21/24) showed same PD-L1 positivity with pre-chemotherapy tissue. The rest showed the decreased PD-L1 positivity after NAC. In cases of TNBC, the increased number of CD8+ T cells was significantly associated with PD-L1 positivity in pre-chemotherapy tissue. (p=0.001) Foxp3+ T cell proportions decreased significantly (p=0.046) and CD8+/Foxp3+ T-cell ratio increased significantly (p=0.023) after NAC. The patients with increased number of CD8+ T cells after NAC had a tendency to live longer without recurrence compared to patients with decreased CD8+ T cells (62.3 vs 38.1 months, p=0.158). Conclusion Our data provides the clinical evidence that PD-L1 positivity are associated with CD8+ T cell proportion and increased CD8+ T cells after NAC might be good prognostic marker. The role of immunologic balance as a prognostic marker for recurrence must be evaluated in future study. Citation Format: Choi YJ, Lee JH, Moon SY, Choi JY, Jung SP, Bae JW, Park KH. Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-24.
Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.
Authors: Yves Deugnier, Bruno Turlin, Martine Ropert, Mohamed Bejaoui, Miranda Athanassiou-Metaxa, Holger Cario, Elliott Vichinsky, Herbert Opitz, Catherine Ressayre-Djaffer, Bertrand Rabault, John Ford
Journal: Blood (2005)
Tigecycline-Based Front-Line Antibiotic Therapy Significantly Decreases Mortality Among Patients with Neutropenic Enterocolitis Following Cytarabine-Containing Chemotherapy for the Remission Induction of Acute Myeloid Leukemia
Authors: Pugliese Novella, Paola Salvatore, Dora Vita Iula, Maria Rosaria Catania, Federico Chiurazzi, Marta Raimondo, Giuliana Beneduce, Claudio Cerchione, Roberta Della Pepa, Claudia Giordano, Luigia Simeone, Fabrizio Pane, Marco Picardi
Journal: Blood (2016)